Autoimmune Disease Programs
Autoimmune Disorders
DiscoveryTarget Discovery
Key Facts
About TScan Therapeutics
TScan Therapeutics is a fully integrated, clinical-stage biotech focused on unleashing the immune system through TCR-T cell therapies. Founded in 2018, the company's lead program, TSC-101, is in a Phase 1 trial for AML and MDS, and it has a pipeline of candidates for solid tumors and autoimmune disorders. TScan differentiates itself with a proprietary platform for target discovery and is advancing both ex vivo and in vivo engineered T cell approaches.
View full company profileTherapeutic Areas
Other Autoimmune Disorders Drugs
| Drug | Company | Phase |
|---|---|---|
| Humira | Royalty Pharma | Commercial |
| Immunomodulation Programs | Fosun Pharma | Various Phases |
| Adalimumab Biosimilar | Glenmark Pharmaceuticals | Phase 3 |
| Autoimmune Diagnostics (Immco) | Trinity Biotech | Approved/Commercial |
| TYK2 Pseudokinase Inhibitor | A2A Pharma | Preclinical |